Obesity Drug One-Year Data Sufficient For Safety and Efficacy – Cmte
This article was originally published in The Pink Sheet Daily
Executive Summary
Weight-loss drug trials should include one-year of data on at least 1,500 patients, FDA’s Endocrinologic & Metabolic Drugs Advisory Committee says. Run-in periods prior to clinical trials are unnecessary, committee members agree.